COMPASS PATHWAYS PLC Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)
COMPASS PATHWAYS PLC (CMPS) reported Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) of $1.14 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-24.
Discontinued › Income Statement › Other Income
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2022-02-24
- COMPASS PATHWAYS PLC fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2019 was $1.14M.
| Period end | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|
| 2019-12-31 | $1.14M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |